GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Nouveau Life Pharmaceuticals Inc (OTCPK:NOUV) » Definitions » ROE %

Nouveau Life Pharmaceuticals (Nouveau Life Pharmaceuticals) ROE % : -556.91% (As of Mar. 2008)


View and export this data going back to . Start your Free Trial

What is Nouveau Life Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Nouveau Life Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2008 was $-0.50 Mil. Nouveau Life Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Mar. 2008 was $0.09 Mil. Therefore, Nouveau Life Pharmaceuticals's annualized ROE % for the quarter that ended in Mar. 2008 was -556.91%.

The historical rank and industry rank for Nouveau Life Pharmaceuticals's ROE % or its related term are showing as below:

NOUV's ROE % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 4.445
* Ranked among companies with meaningful ROE % only.

Nouveau Life Pharmaceuticals ROE % Historical Data

The historical data trend for Nouveau Life Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nouveau Life Pharmaceuticals ROE % Chart

Nouveau Life Pharmaceuticals Annual Data
Trend Jun03 Jun04 Jun05 Jun06
ROE %
- - - -

Nouveau Life Pharmaceuticals Quarterly Data
Jun03 Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -63.09 -160.66 -176.62 -248.20 -556.91

Competitive Comparison of Nouveau Life Pharmaceuticals's ROE %

For the Health Information Services subindustry, Nouveau Life Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nouveau Life Pharmaceuticals's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Nouveau Life Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Nouveau Life Pharmaceuticals's ROE % falls into.



Nouveau Life Pharmaceuticals ROE % Calculation

Nouveau Life Pharmaceuticals's annualized ROE % for the fiscal year that ended in Jun. 2006 is calculated as

ROE %=Net Income (A: Jun. 2006 )/( (Total Stockholders Equity (A: Jun. 2005 )+Total Stockholders Equity (A: Jun. 2006 ))/ count )
=-0.257/( (-0.96+-0.869)/ 2 )
=-0.257/-0.9145
=N/A %

Nouveau Life Pharmaceuticals's annualized ROE % for the quarter that ended in Mar. 2008 is calculated as

ROE %=Net Income (Q: Mar. 2008 )/( (Total Stockholders Equity (Q: Dec. 2007 )+Total Stockholders Equity (Q: Mar. 2008 ))/ count )
=-0.504/( (0.138+0.043)/ 2 )
=-0.504/0.0905
=-556.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2008) net income data. ROE % is displayed in the 30-year financial page.


Nouveau Life Pharmaceuticals  (OTCPK:NOUV) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2008 )
=Net Income/Total Stockholders Equity
=-0.504/0.0905
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.504 / 0)*(0 / 1.2105)*(1.2105 / 0.0905)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*13.3757
=ROA %*Equity Multiplier
=N/A %*13.3757
=-556.91 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2008 )
=Net Income/Total Stockholders Equity
=-0.504/0.0905
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.504 / 0) * (0 / -0.504) * (-0.504 / 0) * (0 / 1.2105) * (1.2105 / 0.0905)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= N/A * 0 * N/A % * 0 * 13.3757
=-556.91 %

Note: The net income data used here is four times the quarterly (Mar. 2008) net income data. The Revenue data used here is four times the quarterly (Mar. 2008) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Nouveau Life Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Nouveau Life Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nouveau Life Pharmaceuticals (Nouveau Life Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
370 Amapola Avenue, Suite 200-A, Torrance, CA, USA, 90501
Nouveau Life Pharmaceuticals Inc is a healthcare solution company that provides non-face-to-face care services. Its product portfolio includes SILBY, Tomy, Amy, Maro, and Kiromy.

Nouveau Life Pharmaceuticals (Nouveau Life Pharmaceuticals) Headlines